AGR2 (D9V2F) XP® Rabbit mAb (BSA and Azide Free) #86533
- WB
- IHC
- IF
- F
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 18 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- IHC-Immunohistochemistry
- IF-Immunofluorescence
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us. Optimal dilutions/concentrations should be determined by the end user.
Formulation
Storage
Specificity / Sensitivity
AGR2 (D9V2F) XP® Rabbit mAb (BSA and Azide Free) recognizes endogenous levels of total AGR2 protein.
Species Reactivity:
Human
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Monkey, Xenopus
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala29 of human AGR2 protein.
Background
Anterior gradient homolog 2 (AGR2) is a member of the protein disulfide isomerase (PDI) family of proteins and a homolog of the Xenopus laevis cement gland protein (1). In normal human tissues, AGR2 is expressed most abundantly in intestinal cells. Research studies have found AGR2 is overexpressed in a number of adenocarcinomas, including those derived from breast, pancreas, ovary, prostate and esophagus (2-4). In vitro and in vivo studies have shown that AGR2 positively regulates cell growth and division, while its overexpression can promote cell transformation (5,6). The latter functions of AGR2 were shown to involve YAP1-mediated up-regulation of amphiregulin expression, implicating AGR2 in both the EGF and Hippo kinase signaling pathways (6).
- Maresh, E.L. et al. (2010) BMC Cancer 10, 680.
- Pizzi, M. et al. (2012) Appl Immunohistochem Mol Morphol 20, 31-6.
- Wang, Z. et al. (2008) Cancer Res 68, 492-7.
- Park, K. et al. (2011) Exp Mol Med 43, 91-100.
- Vanderlaag, K.E. et al. (2010) Breast Cancer Res 12, R32.
- Dong, A. et al. (2011) J Biol Chem 286, 18301-10.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.